Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ProMetic Life Sciences has said that its oral PBI-1402 has demonstrated significant activity in patients with chemotherapy-induced anemia, and reduces the need for red blood cell transfusion.
Subscribe to our email newsletter
Chemotherapy-induced anemia (CIA) patients enrolled in the study received a once daily oral dose of PBI-1402 during a period of eight weeks while undergoing their normal course of chemotherapy. All patients enrolled have completed the PBI-1402 treatment period. Only two patients out of 28 (7%) treated with PBI-1402 required a red blood cell (RBC) transfusion, a response rate greater than 90% with regards to this clinical objective.
Pierre Laurin, president and CEO of ProMetic, said: “These results are very exciting and meet the primary objective that formed the basis for FDA approval of other erythropoiesis-stimulating agents (ESAs) in CIA patients. This new encouraging data further supports the potential role PBI-1402 could play in the management of anemia in patients with cancer.”